Diagnostic Advances
Copyright ©The Author(s) 2016.
World J Gastrointest Pathophysiol. Feb 15, 2016; 7(1): 27-37
Published online Feb 15, 2016. doi: 10.4291/wjgp.v7.i1.27
Table 1 Current biomarkers and their utility in inflammatory bowel disease management[12]
ApplicationBiomarkerUtility
Diagnosis of IBDFecal calprotectin[69]Sensitivity: 89%-98%, specificity: 81%-91%
Fecal lactoferrin[70]Sensitivity: 80%, specificity: 82%
Fecal 100A12[71] (differentiating from IBS)Sensitivity: 86%, specificity: 96%
CRP[72-74]Sensitivity: Approximately equal 100% in CD, approximately equal 50% in UC poor specificity
Distinguishing UC and CDASCA[75]Sensitivity: 40%-50%, specificity: > 90% in CD
pANCA[75]Sensitivity: 57%, specificity: 92%
Escherichia coli antibodies (Anti-OmpC, Anti-I2, Anti-CBir1)[76]Sensitivity: 18%-55%, specificity: 76%-93%[76]
Marker of disease activityFecal lactoferrin[77,78]Sensitivity: 66%-80%
Specificity: 60%-100%
Fecal calprotectin[77,78]Sensitivity: 70%-100%
Specificity: 44%-100%
CRP[78]Sensitivity: 48%
Specificity: 91%
Assessing mucosal healingFecal calprotectinSeveral studies demonstrate significant reduction in biomarker in the presence of mucosal healing with treatment
Predicting disease courseFecal lactoferrin[77]May be associated with complications including; structuring or fistulising disease, and small bowel disease pANCA may predict aggressive UC and pouchitis following surgery[79]
ASCA
pANCA Anti-I2, Anti-OmpC[12]
Predicting Relapse within 12 moFecal calprotectin[80,81]Sensitivity: 69%-90%
Specificity: 69%-82%
Positive predictive value: 81%/87% (UC/CD)
Negative predictive value: 90%/43% (UC/CD)
Fecal lactoferrin[81]Sensitivity: 62%
Specificity: 65%
Predicting therapeutic responsepANCA[82]Conflicting reports, possible lower response rate to infliximab in patients with a positive serology
Anti-I2[83]94% responded to fecal diversion